US 12,466,869 B2
Targeting of multiple antigens with multiplex CAR T cells in solid and liquid malignancies
Carl Novina, Newton, MA (US); Robert J. Distel, Framingham, MA (US); Alberto Nobili, Brookline, MA (US); and Steven C. Neier, Waltham, MA (US)
Assigned to DANA-FARBER CANCER INSTITUTE, INC., Boston, MA (US)
Appl. No. 17/254,472
Filed by DANA-FARBER CANCER INSTITUTE, INC., Boston, MA (US)
PCT Filed Jun. 27, 2019, PCT No. PCT/US2019/039620
§ 371(c)(1), (2) Date Dec. 21, 2020,
PCT Pub. No. WO2020/006312, PCT Pub. Date Jan. 2, 2020.
Claims priority of provisional application 62/697,526, filed on Jul. 13, 2018.
Claims priority of provisional application 62/691,486, filed on Jun. 28, 2018.
Prior Publication US 2021/0137987 A1, May 13, 2021
Int. Cl. C07K 14/725 (2006.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); A61K 47/68 (2017.01); C07K 16/32 (2006.01)
CPC C07K 14/7051 (2013.01) [A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/4202 (2025.01); A61K 40/4205 (2025.01); A61K 40/4217 (2025.01); A61K 40/4222 (2025.01); A61K 40/4258 (2025.01); A61K 47/6865 (2017.08); A61K 47/6867 (2017.08); C07K 16/32 (2013.01); A61K 2239/47 (2023.05); A61K 2239/48 (2023.05); A61K 2239/49 (2023.05); C07K 2319/33 (2013.01)] 20 Claims
 
1. A bifunctional compound comprising a first synthetic antigen covalently linked to a first targeting moiety that binds a first tumor associated antigen, or a pharmaceutically acceptable salt or stereoisomer thereof,
wherein the synthetic antigen comprises a removable protecting group,
wherein the synthetic antigen can bind a CAR-T cell after removal of the removable protecting group, and
wherein the synthetic antigen is 4-[(6-methylpyrazin-2-yl) oxy] benzoate (MPOB) anthraquinone-2-carboxylate (AQ), tetraxetan (DOTA), or a peptidic, glysodic or nucleotidic antigen.